PSAR

Cue Health Announces Appointment of Josh Ghaim, Ph.D. and Sachin Jain, M.D. to its Board of Directors

Retrieved on: 
Thursday, November 17, 2022
Health Technology, Health, Telemedicine, Virtual Medicine, Medical Devices, FDA, Business school, Central Drugs Standard Control Organisation, Merck, Innovation, Office of Inspector General, U.S. Department of Health and Human Services, Chemistry, Cue, Scan Group, Biochemistry, Human services, CE, Molecular biology, Health Canada, Medicine, Pharma, Johnson & Johnson, Doctor of Philosophy, PSAR, AHIP, Bolam v Friern Hospital Management Committee, Boston, Interim order, Harvard University, Champaign County, Illinois, Hand, Stanford University, MBA, The Washington Campus Board of Directors, Union, COVID-19, Medical device, University, CareMore, Management, Pharmaceutical industry, Indiana University, Health

Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D.

Key Points: 
  • Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that Josh Ghaim, Ph.D. and Sachin Jain, M.D.
  • Cue Healths Board now consists of seven directors, five of whom are independent.
  • On behalf of the management team and Board, Im pleased to welcome both Josh and Sachin to the Cue team.
  • Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easier for individuals to access health information and places diagnostic information at the center of care.

Cue Health to Announce Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, October 26, 2022
General Health, Health Technology, Health, Union, Health Sciences Authority, Telephone, Hand, Interim order, Central Drugs Standard Control Organisation, Nasdaq, PSAR, Cue, Health Canada, Health, CE, FDA, COVID-19

Cue Health Inc. (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022.

Key Points: 
  • Cue Health Inc. (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2022 financial results on Wednesday, November 9, 2022.
  • In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
  • Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easier for individuals to access health information and places diagnostic information at the center of care.
  • Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority.

Cue Health Applies with FDA for Emergency Use Authorization of its Cue Flu + COVID-19 Molecular Test

Retrieved on: 
Tuesday, October 4, 2022
Johns Hopkins School of Medicine, Mayo Clinic, Emergency Use Authorization, Health Canada, Major League Baseball, Health Sciences Authority, Federal Food, Drug, and Cosmetic Act, Hospital, SEC, Risk, CE, Nasdaq, Severe acute respiratory syndrome coronavirus 2, Food, CEO, Health, Virus, Central Drugs Standard Control Organisation, Influenza, FDA, National Basketball Association, COVID-19, Annual report, Infection, Degenerative disease, Cue, Hand, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UPMC Children's Hospital of Pittsburgh, SAN, Union, EUA, Compte rendu, De novo, Interim order, PSAR, Diagnosis, National, POC, Urinary tract infection, Medical device, Pharmaceutical industry, Google

SAN DIEGO, Oct. 4, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company that puts diagnostic information at the center of care, today announced that on September 30, 2022, it submitted an application with the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Cue® Flu + COVID-19 Molecular Test for at-home and point-of-care (POC) use.

Key Points: 
  • The new Cue Flu + COVID-19 Molecular Test can simultaneously detect and differentiate between influenza and COVID-19 in approximately 25 minutes, with results delivered digitally to the Cue Health App on the user's mobile device.
  • The Cue Flu + COVID-19 Molecular Test Cartridge uses a lower nasal swab sample and runs on the Cue Reader, which communicates test results digitally to the Cue Health App on a mobile device.
  • Currently, Cue's standalone molecular tests for both flu and COVID-19 are under de novo review with the FDA for full clearance.
  • Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.

Cue Health Appoints Suzanne Stone as New Chief Commercial Officer

Retrieved on: 
Tuesday, September 27, 2022
Central Drugs Standard Control Organisation, Health, Time, Acceleration, COVID-19, Advertising, Cue, FDA, Chief commercial officer, Interim order, Organization, Senior, Growth, Dexcom, PSAR, Hand, Patient, CEO, Health Canada, CE, Nasdaq, MannKind Corporation, Leadership, Health Sciences Authority, Rock (geology), SAN, Marketing, Union, Multimedia, Pharmaceutical industry, Management

SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed Suzanne Stone as its new Chief Commercial Officer.

Key Points: 
  • SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed Suzanne Stone as its new Chief Commercial Officer.
  • "Suzanne is a well-established commercial leader with extensive healthcare experience and an impressive track record of building great teams," said Ayub Khattak, Chairman and CEO of Cue Health.
  • Previously, Stone held a number of executive roles at DexCom, including in sales, global commercial operations, and financial planning.
  • Cue Health ( Nasdaq: HLTH ) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care.

Cue Health Appoints David Tsay, MD, PhD, as Chief Medical Officer

Retrieved on: 
Thursday, September 8, 2022
Cue, Columbia University Irving Medical Center, COVID-19, CEO, Computer science, Columbia University Vagelos College of Physicians and Surgeons, Artificial intelligence, Washington Apple Health, Physician, Hand, Doctor of Philosophy, Columbia University College of Dental Medicine, Central Drugs Standard Control Organisation, Associate, Physics, Internal medicine, Union, Interim order, Health Canada, NYP, Multimedia, Data science, New, MD, Nasdaq, FDA, Communication, CE, Automation, PSAR, Health Sciences Authority, Surgeon, Cardiology, Health, Patient, Medical device, Management, Medicine, Research, Apple

SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David Tsay, MD, PhD, as its Chief Medical Officer. Dr. Tsay comes to Cue with more than 20 years of experience in clinical medicine, research, and health technology. Most recently, Dr. Tsay served at Apple, where he led an Apple Health clinical team in developing new Health products, including FDA-cleared products in cardiovascular health.

Key Points: 
  • Dr. Tsay Brings Two Decades of Expertise in Clinical Medicine, Research, and Health Technology to Cue
    SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that it has appointed David Tsay, MD, PhD, as its Chief Medical Officer.
  • Dr. Tsay comes to Cue with more than 20 years of experience in clinical medicine, research, and health technology.
  • Most recently, Dr. Tsay served at Apple, where he led an Apple Health clinical team in developing new Health products, including FDA-cleared products in cardiovascular health.
  • As Chief Medical Officer, Dr. Tsay will help define future Cue diagnostic products and services.

Cue Health Makes De Novo Submission to FDA for Full Clearance of its Cue® Flu Molecular Test

Retrieved on: 
Thursday, September 1, 2022
Cue, Mayo Clinic, UPMC Children's Hospital of Pittsburgh, COVID-19, EUA, CEO, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, Hand, SAN, Central Drugs Standard Control Organisation, Federal Food, Drug, and Cosmetic Act, Johns Hopkins School of Medicine, Major League Baseball, Virus, Risk, National Basketball Association, Food, Bluetooth, Diagnosis, Union, Interim order, Health Canada, SEC, De novo, Multimedia, Emergency Use Authorization, National, Severe acute respiratory syndrome coronavirus 2, PCR, Hospital, Nasdaq, FDA, Bridgewater, Annual report, Compte rendu, POC, CE, PSAR, Health Sciences Authority, Health, Patient, Pharmaceutical industry, Google

FDA clearance of Cue's test would provide the public, for the first time, an at-home and POC molecular flu test that has been fully reviewed by the FDA for safety and effectiveness.

Key Points: 
  • FDA clearance of Cue's test would provide the public, for the first time, an at-home and POC molecular flu test that has been fully reviewed by the FDA for safety and effectiveness.
  • Clinical study results with the Cue Flu Molecular Test were favorable, demonstrating 99% accuracy1compared to FDA cleared molecular (PCR) laboratory tests for influenza A&B.
  • The Cue Flu Molecular Test cartridge uses a lower nasal swab and is compatible with the Cue Reader, which communicates test results digitally via Bluetooth to a mobile device in approximately 25 minutes.
  • "This FDA submission for our Cue Flu Molecular Test is another important milestone on Cue's path to pioneer a new approach to diagnostics in homes, enterprises, and healthcare settings," said Ayub Khattak, Chairman and CEO of Cue Health.

Cue Health to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, August 30, 2022
General Health, Health Technology, Health, Other Health, COVID-19, Hand, Morgan, Central Drugs Standard Control Organisation, Health, Union, Interim order, Health Canada, Conference, Nasdaq, FDA, CE, PSAR, Health Sciences Authority, Medical device

Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 4:40 p.m. Eastern Time in New York, NY.

Key Points: 
  • Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 4:40 p.m. Eastern Time in New York, NY.
  • Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care.
  • Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand.
  • Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, regulatory approval from India's Central Drugs Standard Control Organization, and PSAR authorization from Singapore's Health Sciences Authority.

Cue Health Launches Cue Care™ Nationwide to Provide Same-Day, At-Home, Test-to-Treatment Service for COVID-19

Retrieved on: 
Monday, August 29, 2022
Mayo Clinic, COVID-19, Office of Inspector General, U.S. Department of Health and Human Services, EUA, CEO, Hospital, Chlamydia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Hand, SAN, RSV, Respiratory syncytial virus, Central Drugs Standard Control Organisation, Federal Food, Drug, and Cosmetic Act, Johns Hopkins School of Medicine, Major League Baseball, Virus, Risk, Gonorrhea, National Basketball Association, Food, Diagnosis, Urinary tract infection, Union, SEC, Interim order, Health Canada, Multimedia, Emergency Use Authorization, National, Severe acute respiratory syndrome coronavirus 2, Patient, Nasdaq, FDA, Pharmacy, Annual report, Compte rendu, CE, PSAR, Health Sciences Authority, Health, HHS, Trial of the century, Pharmaceutical industry, Medicine, Medical device, Cue, Google

Within a few weeks, Cue Health anticipates expanding this new service to patients who test positive on any COVID-19 test, including at-home antigen tests.

Key Points: 
  • Within a few weeks, Cue Health anticipates expanding this new service to patients who test positive on any COVID-19 test, including at-home antigen tests.
  • "Early diagnosis and treatment have shown to lead to better health outcomes, which is why we're proud to deliver timely testing and treatment all within the Cue Health App," said Ayub Khattak, Chairman and CEO of Cue Health.
  • "Cue Care meets the need today for convenient delivery of COVID-19 treatment, and this capability will support our expanding pipeline of future diagnostics tests."
  • Cue Health (Nasdaq: HLTH) is a healthcare technology company that makes it easier for individuals to access health information and places diagnostic information at the center of care.

Independent Study Shows Cue Health's Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

Retrieved on: 
Wednesday, August 17, 2022
FDA, Compte rendu, Multimedia, Hand, Union, Laboratory, Federal Food, Drug, and Cosmetic Act, Emergency Use Authorization, Trial of the century, Population, Diagnosis, POC, EUA, SEC, Workplace, Interim order, RPN NewsWatch Junior Edition, Annual report, FH, CE, PSAR, COVID-19, VP, Cue, Health Canada, Health Sciences Authority, Viral load, RT, Manuscript, Risk, Central Drugs Standard Control Organisation, Infection, Virus, RNS, ISO, Nasdaq, PCR, Severe acute respiratory syndrome coronavirus 2, Development, Ontario Ministry of Citizenship and Immigration, Efficiency, COVID-19 testing, Pharmaceutical industry, Vaccine, Medical device, Health

SAN DIEGO, Calif., Aug. 17, 2022 /PRNewswire/ -- Cue Health Inc. ("Cue") (Nasdaq: HLTH) announced today the preprint publication of an independent clinical study - the largest of its kind on asymptomatic people - demonstrating that its point of care (POC) molecular COVID-19 test, which produces results in approximately 20 minutes, is as accurate as a centralized lab-based RT-PCR.  

Key Points: 
  • The study presents findings from a head-to-head comparison of the Cue COVID-19 test against lab-based RT-PCR on paired samples from 3,037 individuals.
  • "The findings from our large study indicate that sensitivity of Cue's POC testing may be an excellent proxy for PCR when accurate and fast results are urgently needed to curb transmission."
  • Specimen collection and Cue COVID-19 testing was performed by trained registered nurses (RNs and RPNs) at FH Health clinic sites.
  • Cue Health's first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.

Cue Health to Participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

Retrieved on: 
Wednesday, August 3, 2022
Health, Technology, Other Technology, Health Technology, Other Health, General Health, Central Drugs Standard Control Organisation, COVID-19, CE, Union, Health, Health Sciences Authority, Nasdaq, FDA, Interim order, PSAR, Hand, Conference, Health Canada, Medical device

Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.

Key Points: 
  • Cue Health (Cue) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference on Tuesday, August 16, 2022.
  • Cue is a healthcare technology company that makes it easy for individuals to access health information and places diagnostic information at the center of care.
  • Cue enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand.
  • Cues first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.